Bianano Genomics Lineagen EpiPanel Dx Plus
Bionano Genomics' recent acquisition Lineagen has launched the EpiPanel Dx Plus, a laboratory-developed test for epilepsy-related conditions.
The proprietary gene panel is based on 223 genes selected from a literature review, including genes with pathogenic variants identified in more than 2,000 epileptic patients tested by Lineagen. The test is designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures and can predict the recurrence risk for other members of the family and allows for personalized treatment. It has an expected diagnostic yield of 30 percent.